A61K 51/02
Preparations containing radioactive substances for use in therapy or testing in vivo
Official title: characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus}
A61K51/02 (Preparations containing radioactive substances for use in therapy or testing in vivo) appears on 5,825 US grants and 7,726 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,825
- Published applications
- 7,726
- Assignees
- 2,412
- Inventors
- 12,592
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 17 | 0 |
| 1977 | 24 | 0 |
| 1978 | 16 | 0 |
| 1979 | 3 | 0 |
| 1980 | 16 | 0 |
| 1981 | 19 | 0 |
| 1982 | 34 | 0 |
| 1983 | 14 | 0 |
| 1984 | 50 | 0 |
| 1985 | 23 | 0 |
| 1986 | 23 | 0 |
| 1987 | 32 | 0 |
| 1988 | 27 | 0 |
| 1989 | 59 | 0 |
| 1990 | 59 | 0 |
| 1991 | 71 | 0 |
| 1992 | 82 | 0 |
| 1993 | 73 | 0 |
| 1994 | 93 | 0 |
| 1995 | 94 | 0 |
| 1996 | 91 | 0 |
| 1997 | 150 | 0 |
| 1998 | 170 | 0 |
| 1999 | 157 | 0 |
| 2000 | 126 | 0 |
| 2001 | 107 | 35 |
| 2002 | 91 | 131 |
| 2003 | 92 | 201 |
| 2004 | 79 | 221 |
| 2005 | 81 | 237 |
| 2006 | 108 | 223 |
| 2007 | 77 | 216 |
| 2008 | 111 | 233 |
| 2009 | 107 | 264 |
| 2010 | 135 | 299 |
| 2011 | 136 | 286 |
| 2012 | 173 | 271 |
| 2013 | 209 | 324 |
| 2014 | 227 | 389 |
| 2015 | 231 | 361 |
| 2016 | 238 | 410 |
| 2017 | 266 | 335 |
| 2018 | 235 | 344 |
| 2019 | 236 | 351 |
| 2020 | 234 | 372 |
| 2021 | 218 | 362 |
| 2022 | 191 | 392 |
| 2023 | 180 | 336 |
| 2024 | 185 | 435 |
| 2025 | 198 | 389 |
| 2026 | 157 | 309 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Composition containing buffer6 Oct 2026US 12,752,008 B2Perseus Proteomics Inc.
- Near-infrared dyes and conjugates for targeting tumors6 Oct 2026US 12,752,023 B2Lahjavida, LLC
- Fibroblast activation protein inhibitor6 Oct 2026US 12,752,025 B2Boomray Pharmaceuticals Co., Ltd.
- Radiopharmaceutical compositions for actinium in targeted radionuclide therapy6 Oct 2026US 12,752,026 B2Curium US LLC
- Peptide libraries with non-canonical amino acids6 Oct 2026US 12,753,205 B2Regeneron Pharmaceuticals, Inc.
- Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents8 Oct 2026US 2026/0306634 A1Wisconsin Alumni Research Foundation
- Radiolabeled compounds targeting the prostate-specific membrane antigen8 Oct 2026US 2026/0306680 A1Provincial Health Services Authority
- Development of a platform to noninvasively image car t cells8 Oct 2026US 2026/0306681 A1Dana-Farber Cancer Institute, Inc.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- In vivo imaging of an als biomarker and means therefor8 Oct 2026US 2026/0306683 A1AL-S Pharma AG
Most cited
By later US patents
- Medical scanning and treatment system and method1,502US 5,464,013 A1995
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers510US 4,331,647 A1982
- Radioactive embolizing compositions503US 6,015,541 AMicro Therapeutics, Inc. · 2000
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009